Pliant Therapeutics, Inc , a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.
infoPliant Therapeutics is a small cap stock with a total market cap of 1.02B.
infoThey trade on the NASDAQ and had their IPO 3 years and 2 months ago.
infoPliant Therapeutics currently employs 155 people.
infoAs of Wednesday, Aug 23 2023, Pliant Therapeutics’s share price is $16.99.
News Relating to Pliant Therapeutics
Seeking Alpha
Pliant Therapeutics: Promising Phase 2a Bexotegrast Data Unveiled
Friday Aug 11 2023 at 12:19
Pliant Therapeutics is a biotech company focused on developing therapies for fibrotic diseases. The company’s financials show an increase in R&D and administrative expenses, as well as a net loss, but it has a strong liquidity position. Pliant’s pipeline includes two clinical-stage programs targeting fibrosis pathways, with promising early results for their lead program, bexotegrast.
Zacks Investment Research
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates
Wednesday Aug 09 2023 at 18:59
Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.82 per share a year ago.
GlobeNewsWire
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Tuesday Jul 25 2023 at 08:00
SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following August investor conferences.
Zacks Investment Research
Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates
Tuesday May 09 2023 at 19:06
Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.78 per share a year ago.
Seeking Alpha
Pliant Therapeutics: A Breath Of Fresh Air For A Multibillion Dollar IPF Market
Saturday Apr 15 2023 at 07:55
Pliant Therapeutics: A Breath Of Fresh Air For A Multibillion Dollar IPF Market
InvestorPlace
7 Biotech Stocks to Buy for 100% Returns
Sunday Apr 09 2023 at 13:19
Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1.02 trillion in 2021.
Zacks Investment Research
Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates
Thursday Mar 09 2023 at 19:49
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -2.86% and 27.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Pliant Therapeutics’ Bexotegrast Shows Promise For Idiopathic Pulmonary Fibrosis
Friday Mar 03 2023 at 10:48
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for fibrosis, inflammation, and related diseases. Its lead drug, bexotegrast, is being developed for Idiopathic Pulmonary Fibrosis (IPF). Bexotegrast is a small molecule dual selective inhibitor of αvß6 and αvß1 integrins, with the potential to reduce fibrosis while promoting tissue repair and regeneration.
The Motley Fool
Why Pliant Therapeutics Stock Is Skyrocketing This Week
Thursday Jan 26 2023 at 16:16
The company’s experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.
MarketBeat
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Thursday Jan 26 2023 at 04:23
Patients with this condition have difficulty breathing due to a buildup of lung scar tissue. They have difficulty breathing due to built-up scar tissue in their lungs.
Zacks Investment Research
Pliant Therapeutics (PLRX) Surges 44% in A Week: Here’s Why
Wednesday Jan 25 2023 at 12:02
Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.
Investors Business Daily
An Unexpected Feat Just Sent Pliant Therapeutics Soaring More Than 50%
Monday Jan 23 2023 at 10:12
Pliant Therapeutics unveiled promising results for a lung disease treatment on Monday, and PLRX stock rocketed into the stratosphere. The post An Unexpected Feat Just Sent Pliant Therapeutics Soaring More Than 50% appeared first on Investor’s Business Daily.
Market Watch
Pliant Therapeutics shares rally 75%
Monday Jan 23 2023 at 07:49
Shares of Pliant Therapeutics Inc. PLRX, +2.62% soared about 75% in premarket trading on Monday, the day after the company said a high dose of its experimental treatment for idiopathic pulmonary fibrosis met the primary and secondary endpoints in a Phase 2a clinical trial. Pliant, which is testing four different doses of bexotegrast, said 21 patients received the 320 milligram dose — the highest dose — and will continue to receive treatment for 24 weeks.
Zacks Investment Research
Strength Seen in Pliant Therapeutics, Inc. (PLRX): Can Its 8.3% Jump Turn into More Strength?
Thursday Jan 12 2023 at 06:02
Pliant Therapeutics, Inc. (PLRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Seeking Alpha
Pliant Therapeutics: Wait For More Data Clarity On Dose-Dependent Response In FVC
Friday Dec 16 2022 at 03:48
Pliant Therapeutics’ phase 2a data does not show a dose-dependent response in FVC. I discussed some of the other confusing issues here.
GlobeNewsWire
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Tuesday Nov 15 2022 at 08:00
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following November investor conferences:
Zacks Investment Research
Pliant Therapeutics, Inc. (PLRX) Reports Q3 Loss, Misses Revenue Estimates
Tuesday Nov 08 2022 at 18:48
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 12.16% and 34.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research
Has Pliant Therapeutics (PLRX) Outpaced Other Medical Stocks This Year?
Tuesday Sep 06 2022 at 11:17
Here is how Pliant Therapeutics, Inc. (PLRX) and Alaunos (TCRT) have performed compared to their sector so far this year.
Zacks Investment Research
Pliant Therapeutics, Inc. (PLRX) Upgraded to Buy: What Does It Mean for the Stock?
Monday Sep 05 2022 at 13:33
Pliant Therapeutics, Inc. (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research
Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose
Friday Sep 02 2022 at 13:32
Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company’s lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.
Zacks Investment Research
How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 127%
Thursday Sep 01 2022 at 11:34
The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Pliant Therapeutics, Inc. (PLRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GlobeNewsWire
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Tuesday Aug 30 2022 at 08:00
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and members of Pliant’s senior management will participate in the following September investor conferences:
Seeking Alpha
Pliant Therapeutics: Wait For A Better Price To Get In
Saturday Aug 20 2022 at 06:07
PLRX went up 200% on strong phase 2a data in IPF. Even a subsequent large dilution was unable to dampen enthusiasm.
Zacks Investment Research
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Tuesday Aug 09 2022 at 09:02
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.
Zacks Investment Research
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Tops Revenue Estimates
Monday Aug 08 2022 at 18:48
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 0% and 269.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
InvestorPlace
7 Cheap Biotech Stocks to Buy Now
Wednesday Aug 03 2022 at 16:42
Biopharmaceutical companies have been struggling since 2021 and that narrative isn’t immediately changing. However, not every firm deserves this fate.
The Motley Fool
2022 Roundtable: Our Favorite Picks Right Now
Sunday Jul 24 2022 at 10:00
Here’s why we like Novavax, Orthopediatrics, and Pliant Therapeutics.
Zacks Investment Research
Pliant Therapeutics (PLRX) Up on Positive Data From Lung Disease Study
Tuesday Jul 12 2022 at 12:20
Pliant Therapeutics (PLRX) reports favorable data from a mid-stage study, which supports the potential of PLN-74809, its experimental drug candidate for treating IPF.
Benzinga
What’s Going On With Pliant Therapeutics Stock?
Tuesday Jul 12 2022 at 08:47
Pliant Therapeutics Inc (NASDAQ: PLRX) shares are trading lower Tuesday after the company announced a proposed $150 million offering. Pliant Therapeutics shares soared by nearly 160% Monday on the company’s treatment for Idiopathic Pulmonary Fibrosis, which was.
Zacks Investment Research
Pliant Therapeutics, Inc. (PLRX) Stock Jumps 159%: Will It Continue to Soar?
Tuesday Jul 12 2022 at 06:12
Pliant Therapeutics, Inc. (PLRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn’t suggest further strength down the road.
Pliant Therapeutics Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Pliant Therapeutics’s Altman Z-score is 13.78 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
Pliant Therapeutics Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $698.58K of common stock in Pliant Therapeutics on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Pliant Therapeutics’s Income Quality of 0.79 is greater than its Industry Group of 0.69 (14.5% greater)
Pliant Therapeutics’s Income Quality of 0.79 is greater than its Major Industry Group of 0.71 (11.3% greater)
Pliant Therapeutics’s Income Quality of 0.79 is in line with its Sector of 0.75 (5.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Pliant Therapeutics’s Current Ratio of 19.16 is greater than its Industry Group of 4.76 (302.5% greater)
Pliant Therapeutics’s Current Ratio of 19.16 is greater than its Major Industry Group of 4.32 (343.5% greater)
Pliant Therapeutics’s Current Ratio of 19.16 is greater than its Sector of 2.6 (636.9% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-7.71 & -1.27)
Cannot compare a negative PE Ratio (-7.71 & -1.1)
Cannot compare a negative PE Ratio (-7.71 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Pliant Therapeutics’s PB Ratio of 1.91 is greater than its Industry Group of 1.34 (42.5% greater)
Pliant Therapeutics’s PB Ratio of 1.91 is greater than its Major Industry Group of 1.4 (36.4% greater)
Pliant Therapeutics’s PB Ratio of 1.91 is greater than its Sector of 1.62 (17.9% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Pliant Therapeutics’s ROE of -0.25 is greater than its Industry Group of -0.44 (43.2% greater)
Pliant Therapeutics’s ROE of -0.25 is greater than its Major Industry Group of -0.38 (34.2% greater)
Pliant Therapeutics’s ROE of -0.25 is lower than its Sector of -0.03 (-733.3% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Pliant Therapeutics’s ROCE of -0.29 is greater than its Industry Group of -0.42 (31.0% greater)
Pliant Therapeutics’s ROCE of -0.29 is greater than its Major Industry Group of -0.37 (21.6% greater)
Pliant Therapeutics’s ROCE of -0.29 is lower than its Sector of -0.04 (-625.0% lower)
Derived from SEC.GOV filing dataopen_in_new